Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osprey study of intramuscular methotrexate for unruptured ectopic pregnancy
ISRCTN75251780Phase 3Completed
- Sponsor
- Accord Healthcare
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of methotrexate in Ectopic pregnancy (EP), sponsored by Accord Healthcare. Primary endpoints: Incidence of related adverse events and Changes in hematological, renal and liver function tests. Started Jul 2021; status: completed.
02
Drugs
methotrexate
03
Conditions
Ectopic pregnancy (EP)
Beyond the preview
Go deeper on ISRCTN75251780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN75251780.